Aldosterone and Left Ventricular Remodeling

Hormone and Metabolic Research

Volumn 47, Issue 13, 2015, Pages 981-986

  Catena, C ^a   Colussi, G ^a   Brosolo, G ^a   Novello, M ^a   Sechi, L A ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

diastolic dysfunction; essential hypertension; heart failure; left ventricular hypertrophy; primary aldosteronism; salt intake

Indexed keywords

ALDOSTERONE; SODIUM CHLORIDE;

CLINICAL STUDY; CLINICAL TRIAL (TOPIC); DIASTOLIC HEART FAILURE; ESSENTIAL HYPERTENSION; GEOMETRY; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART INJURY; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE MASS; HEART VENTRICLE REMODELING; HUMAN; NONHUMAN; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SALT INTAKE; SYSTOLIC HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE; HYPERALDOSTERONISM; HYPERTENSION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

ALDOSTERONE; HEART VENTRICLES; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84951569366     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0035-1565055     Document Type: Review

References (65)

1. Pitt B., Zannad F., Remme W. J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med: 1999; 341 709 717
2. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., Bittman R., Hurley S., Kleiman J., Gatlin M. Eplerenone a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med: 2003; 348 1309 1321
3. Zannad F., McMurray JJ V., Krum H., van Veldhuisen D. J., Swedberg K., Shi H., Vincent J., Pocock S. J., Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med: 2011; 364 11 21
4. Catena C., Colussi G. L., Marzano L., Sechi L. A. Aldosterone and the heart: from basic research to clinical evidence. Horm Metab Res: 2012; 44 181 187
5. Lombes M., Alfaidy N., Eugene E., Lessana A., Farman A., Bonvalet J. P. Prerequisite for cardiac aldosterone action: mineralocorticoid receptor and 11-β-hydroxysteroid dehydrogenase in the human heart. Circulation: 1995; 92 175 182
6. Marney A. M., Brown N. J. Aldosterone and end-organ damage. Clin Sci: 2007; 113 267 278
7. Catena C., Colussi G. L., Nait F., Martinis F., Pezzutto F., Sechi L. A. Aldosterone and the heart: still an unresolved issue? Front Endocrinol: 2014; 5 1 5
8. Rocha R., Stier C. T. Jr, Kifor I., Ochoa-Maya M. R., Rennke H. G., Williams G. H., Adler G. K. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology: 2000; 141 3871 3878
9. Brilla C. G., Weber K. T. Mineralcocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med: 1992; 120 893 901
10. Martinez D. V., Rocha R., Matsumura M., Oestreicher E., Ochoa-Maya M., Roubsanthisuk W., Williams G. H., Adler G. K. Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading. Hypertension: 2002; 39 614 618
11. Frohlich E. D. Left ventricular hypertrophy: an independent risk factor. Cardiovasc Clin: 1990; 20 85 94
12. Drazner M. H. The progression of hypertensive heart disease. Circulation: 2011; 123 327 334
13. Edelman F., Tomaschitz A., Wachter R., Gelbrich G., Knoke M., Düngen H. D., Pilz S., Binder L., Stahrenberg R., Schmidt A., März W., Pieske B. Serum aldosterone and its relationship to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction. Eur Heart J: 2012; 33 203 212
14. Velagaleti R. S., Gona P., Levy D., Aragam J., Larson M. G., Tofler G. H., Lieb W., Wang T. J., Benjamin E. J., Vasan R. S. Relations of biomarkers representing distinct biological pathways to left ventricular geometry. Circulation: 2008; 118 2252 2258
15. Li R., Richey P. A., DiSessa T. G., Alpert B. S., Jones D. P. Blood-aldosterone-to-renin ratio, ambulatory blood pressure, and left ventricular mass in children. J Pediatr: 2009; 155 170 175
16. Stowasser M., Sharman J., Leano R., Gordon R. D., Ward G., Cowley D., Marwick T. H. Evidence of abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab: 2005; 90 5070 5076
17. Denolle T., Chatellier G., Julien J., Battaglia C., Luo P., Plouin P. F. Left ventricular mass and geometry before and after etiologic treatment in renovascular hypertension, aldosterone-producing adenoma, and pheochromocytoma. Am J Hypertens: 1993; 6 907 913
18. Rossi G. P., Sacchetto A., Visentin P., Canali C., Graniero G. L., Palatini P., Pessina A. C. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension: 1996; 27 1039 1045
19. Rossi G. P., Sacchetto A., Pavan E., Palatini P., Graniero G. R., Canali C., Pessina A. C. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation: 1997; 95 1471 1478
20. Shigematsu Y., Mareomi H., Hideki O., Hara Y., Hayashi Y., Kodama K., Katsuhiko K., Hiwada K. Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism. Hypertension: 1997; 29 723 727
21. Tanabe A., Naruse M., Naruse K., Hase M., Yoshimoto T., Tanaka M., Seki M., Demura R., Demura H. Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension. Hypertens Res: 1997; 20 85 90
22. Catena C., Colussi G., Lapenna R., Nadalini E., Chiuch A., Gianfagna P., Sechi L. A. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension: 2007; 50 911 918
23. Hung C. S., Ho Y. L., Chang Y. Y., Wu V. C., Wu X. M., Lee J. K., Chueh S. C., Lin Y. H., Changh Y. S., Yang S. Y., Hu Y. H., Sui M. J., Chen M. F., Wu KD. Twenty-four-hour urinary aldosterone predicts inappropriate left ventricular mass index in patients with primary aldosteronism. Sci World J: 2013; 294594
24. Muiesan M. L., Salvetti M., Paini A., Agabiti-Rosei C., Monteduro C., Galbassini G., Belotti E., Aggiusti C., Rizzoni D., Castellano M., Agabiti-Rosei E. Inappropriate left ventricular mass in patients with primary aldosteronism. Hypertension: 2008; 52 529 534
25. Rossi G. P., Bello V., Ganzaroli C., Sacchetto A., Cesari M., Bertini A., Giorgi D., Scognamiglio R., Mariani M., Pessina A. C. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension: 2002; 40 23 27
26. Catena C., Colussi G. L., Marzano L., Sechi L. A. Predictive factors of left ventricular mass changes after treatment of primary aldosteronism. Horm Metab Res: 2012; 44 188 193
27. Rossi G. P., Cesari M., Cuspidi C., Maiolino G., Cicala M. V., Bisogni V., Mantero F., Pessina A. C. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension: 2013; 62 62 69
28. Giacchetti G., Ronconi V., Turchi F., Agostinelli L., Mantero F., Rilli S., Boscaro M. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens: 2007; 25 177 186
29. Bernini G., Bacca A., Carli V., Carrara D., Materazzi G., Berti P., Miccoli P., Pisano R., Tantardini V., Bernini M., Taddei S. Cardiovascular changes in patients with primary aldosteronism after surgical or medical treatment. J Endocr Invest: 2012; 35 274 280
30. Marzano L., Colussi G. L., Sechi L. A., Catena C. Adrenalectomy is comparable to medical treatment for reduction of left ventricular mass in primary aldosteronism: meta-analysis of long-term studies. Am J Hypertens: 2015; 28 312 318
31. Sechi L. A., Colussi G. L., Catena C. Hyperaldosteronism and left ventricular hypertrophy. Hypertension: 2010; 56 e26
32. Nakahara T., Takata Y., Hirayama Y., Asano K., Adachi H., Shiokawa G., Sumi T., Ogawa T., Yamashina A. Left ventricular hypertrophy and geometry in untreated essential hypertension is associated with blood levels of aldosterone and procollagen type III amino-terminal peptide. Circ J: 2007; 71 716 721
33. Stewart A. D., Millasseau S. C., Dawes M., Kyd P. A., Chambers J. B., Ritter J. M., Chowienczyk P. J. Aldosterone and left ventricular hypertrophy in Afro-Caribbean subjects with low renin hypertension. Am J Hypertens: 2006; 19 19 24
34. Mulè G., Nardi E., Cusimano P., Cottone S., Seddio G., Geraci C., Palermo A., Andronico G., Cerasola G. Plasma aldosterone and its relationships with left ventricular mass in essential hypertensive patients with the metabolic syndrome. Am J Hypertens: 2008; 21 1055 1061
35. Catena C., Colussi G., Valeri M., Sechi L. A. Association of aldosterone with left ventricular mass in hypertension: interaction with plasma fibrinogen levels. Am J Hypertens: 2013; 26 111 117
36. Iwashima Y., Horio T., Kuroda S., Takishita S., Kawano Y. Influence of plasma aldosterone on left ventricular geometry and diastolic function in treated essential hypertension. Hypertens Res: 2002; 25 49 56
37. Sato A., Hayashi M., Saruta T. Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension. Hypertension Res: 2002; 25 837 842
38. Taniguchi I., Kawai M., Date T., Yoshida S., Seki S., Taniguchi M., Shimizu M., Mochizuki S. Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. Circ J: 2006; 70 995 1000
39. Pitt B., Reichek N., Willenbrock R., Zannad F., Phillips R. A., Roniker B., Kleiman J., Krazuse S., Burns D., Williams G. H. Effects of eplerenone, enalalpril, and eplerenone/enelapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation: 2003; 108 1831 1839
40. Gaddam K., Corros C., Pimenta E., Ahmed M., Denney T., Aban I., Inusah S., Gupta H., Lloyd S. G., Oparil S., Husain A., Dell'Italia L. J., Calhoun D. A. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective study. Hypertension: 2010; 55 1137 1142
41. Rocha R., Rudolph A. E., Frierdich G. E., Nachowiak D. A., Kekec B. K., Blomme E. A., McMahon E. G., Delyani J. A. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol (Heart Circ Physiol): 2002; 283 H1802 H1810
42. Funder J. W. Mineralocorticoid receptor activation and oxidative stress. Hypertension: 2007; 50 840 841
43. Catena C., Colussi G. L., Sechi L. A. Aldosterone, organ damage and dietary salt. Clin Exp Pharmacol Physiol: 2013; 40 922 928
44. Funder J. W. Primary aldosteronism and salt. Plugers Arch: 2015; 467 587 594
45. Schlaich M. P., Schobel H. P., Hilgers K., Schmieder R. E. Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjects. Am J Cardiol: 2000; 85 1199 1206
46. Jin Y., Kuznetsova T., Maillard M., Richart T., Thijs L., Bochud M., Herregods M. C., Burnier M., Fagard R., Staessen J. A. Independent relations of left ventricular structure with the 24-hour urinary excretion of sodium and aldosterone. Hypertension: 2009; 54 489 495
47. du Cailar G., Fesler P., Ribstein J., Mimran A. Dietary sodium, aldosterone, and left ventricular mass changes during long-term inhibition of the renin-angiotensin system. Hypertension: 2010; 56 865 870
48. Pimenta E., Gordon R. D., Ahmed A. H., Cowley D., Leano R., Marwick T. H., Stowasser M. Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: Results of a case-control study. J Clin Endocrinol Metab: 2011; 26 2813 2820
49. Funder J. W., Carey R. M., Fardella C., Gomez-Sanchez C. E., Mantero F., Stowasser M., Young W. F. Jr, Montori V. M. Endocrine Society Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab: 2008; 93 3266 3281
50. Catena C., Verheyen N. D., Url-Michitsch M., Kraigher-Krainer E., Colussi G., Pilz S., Tomaschitz A., Pieske B., Sechi L. A. Association of post-saline load plasma aldosterone levels with left ventricular hypertrophy in primary hypertension. Am J Hypertens: 2015; July 10 [Epub ahead of print]
51. Catena C., Colussi G. L., Brosolo G., Iogna-Prat L., Sechi L. A. Aldosterone and aldosterone antagonists in cardiac disease: what is known, what is new. Am J Cardiovasc Dis: 2012; 2 50 57
52. Habibi J., DeMarco V. G., Ma L., Pulakat L., Rainey W. E., Whaley-Connell A. T., Sowers J. R. Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression. Am J Physiol (Heart Circ Physiol): 2002; 300 H1484 H1491
53. Ferrari R., Bohm M., Cleland J. G., Paulus W. J., Pieske B., Rapezzi C., Tavazzi L. Heart failure with preserved ejection fraction: uncertainties and dilemmas. Eur J Heart Fail: 2015; 17 665 671
54. Mak G. J., Ledwidge M. T., Watson C. J., Phelan D. M., Dawkins I. R., Murphy N. F., Patle A. K., Baugh J. A., McDonald K. M. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol: 2009; 54 1674 1682
55. Edwards N. C., Ferro C. J., Kirkwood H., Chue C. D., Young A. A., Stewart P. M., Steeds R. P., Townsends J. N. Effect of spironolactone on left ventricular systolic and diastolic in patients with early stage chronic kidney disease. Am J Cardiol: 2010; 106 1505 1511
56. Mottram P. M., Haluska B., Leano R., Cowley D., Stowasser M., Marwick T. H. Effect of aldosteronism antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation: 2004; 110 558 565
57. Edelmann F., Watcher R., Schmidt A. G., Kraigher-Krainer E., Colantonio C., Kamke W., Duvinage A., Stahrenberg R., Durstewitz K., Loffler M., Dungen H. D., Tschope C., Herrmann-Lingen C., Halle M., Hansenfuss G., Gelbrich G., Pieske B. Aldo-DHF Investigators Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA: 2013; 309 781 791
58. Pitt B., Pfeffer M. A., Assmann S. F., Boineau R., Anand I. S., Clagett B., Clausell N., Desai A. S., Diaz R., Fleg J. L., Gordeev I., Harty B., Heitner J. F., Kenwood C. T., Lewis E. F., O'Meara E. O., Probsfield J. L., Shaburishvili T., Shah S. J., Solomon S. D., Sweitzer N. K., Yang S., McKinlay S. M. Spironolactone for heart failure with preserved ejection fraction. NEJM: 2014; 370 1383 1392
59. Pfeffer M. A., Claggett B., Assmann S. F., Boineau R., Anand I. S., Clausell N., Desai A. S., Diaz R., Fleg J. L., Gordeev I., Heitner J. F., Lewis E. F., O'Meara E., Rouleau J. L., Probstfield J. L., Shaburishvili T., Shah S. J., Solomon S. D., Sweitzer N. K., McKinlay S. M., Pitt B. Regional variation in patients and outcomes in the Treatment of preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation: 2015; 131 34 42
60. Freel E. M., Mark P. B., Weir R. A., McQuarrie E. P., Allan K., Dargie H. J., McClure J. D., Jardine A. G., Davies E., Connell J. M. Demonstration of blood pressure-independent noninfarct myocardial fibrosis in primary aldosteronism: a cardiac magnetic resonance imaging study. Circ Cardiovasc Imaging: 2012; 5 740 747
61. Chang Y. Y., Lee H. H., Hung C. S., Wu X. M., Lee J. K., Wang S. M., Liao M. T., Chen Y. H., Wu V. C., Wu K. D., Lin Y. H. TAIPAI Group Association between urine aldosterone and diastolic function in patients with primary aldosteronism and essential hypertension. Clin Biochem: 2014; 47 1329 1332
62. Grandi A. M., Imperiale D., Santillo R., Barlocco E., Bertolini A., Guasti L., Venco A. Aldosterone antagonist improves diastolic function in essential hypertension. Hypertension: 2002; 40 647 652
63. Gupta A., Schiros C. G., Gaddam K. K., Aban I., Denney T. S., Lloyd S. G., Oparil S., Dell'Italia L. J., Calhoun D. A., Gupta H. Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy. J Hum Hypertens: 2015; 29 241 246
64. Catena C., Verheyen N., Pilz S., Kraigher-Krainer E., Tomaschitz A., Sechi L. A., Pieske B. Plasma aldosterone and left ventricular diastolic function in treatment-naïve patients with hypertension: a Tissue-Doppler Imaging Study. Hypertension: 2015; 65 1231 1237
65. Bess R. L., Khan S., Rosman H. S., Cohen G. I., Allebban Z., Gardin J. M. Technical aspects of diastology: why mitral inflow and tissue Doppler imaging are the preferred parameters? Echocardiography: 2006; 23 332 339